Research programme: thrombosis and coagulation disorder therapies - Thrombotargets

Drug Profile

Research programme: thrombosis and coagulation disorder therapies - Thrombotargets

Alternative Names: TT-105; TT-111; TT-112; TT-113; TT-114; TT-115; TT-116; TT-120; TT-123; TT-C01

Latest Information Update: 29 May 2012

Price : $50

At a glance

  • Originator Thrombotargets Corporation
  • Class Monoclonal antibodies; Peptides; Recombinant proteins; Small molecules
  • Mechanism of Action Antifibrinolytic agents; Fibrinolytic agents; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Blood coagulation disorders; Thrombosis

Most Recent Events

  • 28 May 2012 Early research in Thrombosis [Parenteral; PO] and Coagulation disorders [Parenteral] is ongoing in USA and the European Union
  • 30 Apr 2012 Early research in Coagulation disorders in European Union (Topical)
  • 30 Apr 2012 Early research in Coagulation disorders in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top